Drug intelligence / Profile preview

SHR-1901

Development stage: Phase 1
Lead developer: Suzhou Suncadia Biopharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SHR-1901 is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1; PDCD1; CD279), a negative immunoregulatory receptor expressed on human cells. By binding to PD-1, SHR-1901 acts as an immune checkpoint inhibitor, potentially enhancing antitumor immune responses and exhibiting antineoplastic activity. It is being developed for the treatment of advanced malignant tumors and is currently in Phase 1 clinical trials. The drug is under development by Suzhou Suncadia Biopharmaceuticals.

Other names: anti-PD-1 monoclonal antibody SHR-1901anti-PD1 monoclonal antibody SHR-1901anti-PD 1 monoclonal antibody SHR-1901

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on SHR-1901.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHR-1901.

Explore the full profile